AGTC
Applied Genetic Technologies Corporation [AGTC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AGTC Stock Summary
In the News
AGTC Financial details
Company Rating
Buy
Market Cap
0
Income
-35.25M
Revenue
325K
Book val./share
0.27
Cash/share
0.53
Dividend
-
Dividend %
-
Employees
102
Optionable
No
Shortable
Yes
Earnings
13 Feb 2023
P/E
-1.52
Forward P/E
-
PEG
0.32
P/S
-
P/B
1.45
P/C
-
P/FCF
-
Quick Ratio
1.29
Current Ratio
1.4
Debt / Equity
1.14
LT Debt / Equity
0.6
-
-
EPS (TTM)
-0.93
EPS next Y
-
EPS next Q
-
EPS this Y
-10.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
6.15%
Revenue last 5Y
-57.77%
Revenue Q/Q
-
EPS Q/Q
-161.9%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
18.93%
Inst Trans
0.77%
ROA
-29%
ROE
-54%
ROC
-1.04%
Gross Margin
100%
Oper. Margin
-9790%
Profit Margin
-5174%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.2303-2.825
52W High
-
52W Low
-
RSI
-
Rel Volume
0.58
Avg Volume
1.32M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.58361
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
AGTC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-06-30
| Metric | History | 2018-06-30 | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.34 | 2.3 | 0.12 | 0.02 | 0.01 | |
| Net income per share | -1.18 | -0.11 | -2.17 | -1.77 | -1.59 | |
| Operating cash flow per share | -1.8 | -1.29 | -1.97 | -1.56 | -1.46 | |
| Free cash flow per share | -1.84 | -1.31 | -2.03 | -1.62 | -1.5 | |
| Cash per share | 5.79 | 4.52 | 3.81 | 3.27 | 1.03 | |
| Book value per share | 5.48 | 4.33 | 3.37 | 2.62 | 0.65 | |
| Tangible book value per share | 5.42 | 4.28 | 3.31 | 2.58 | 0.62 | |
| Share holders equity per share | 5.48 | 4.33 | 3.37 | 2.62 | 0.65 | |
| Interest debt per share | 0 | 0 | 0.51 | 0.79 | 0.56 | |
| Market cap | 66.99M | 67.18M | 116.91M | 128.08M | 34.67M | |
| Enterprise value | 35.92M | 40.48M | 89.23M | 47.5M | 10.78M | |
| P/E ratio | -3.15 | -33.49 | -2.55 | -2.21 | -0.49 | |
| Price to sales ratio | 2.77 | 1.61 | 47.66 | 256.15 | 106.69 | |
| POCF ratio | -2.06 | -2.86 | -2.81 | -2.5 | -0.53 | |
| PFCF ratio | -2.01 | -2.83 | -2.73 | -2.41 | -0.51 | |
| P/B Ratio | 0.68 | 0.85 | 1.65 | 1.49 | 1.18 | |
| PTB ratio | 0.68 | 0.85 | 1.65 | 1.49 | 1.18 | |
| EV to sales | 1.49 | 0.97 | 36.37 | 95.01 | 33.17 | |
| Enterprise value over EBITDA | -1.79 | -61.61 | -2.01 | -0.83 | -0.17 | |
| EV to operating cash flow | -1.1 | -1.73 | -2.14 | -0.93 | -0.16 | |
| EV to free cash flow | -1.08 | -1.7 | -2.08 | -0.9 | -0.16 | |
| Earnings yield | -0.32 | -0.03 | -0.39 | -0.45 | -2.06 | |
| Free cash flow yield | -0.5 | -0.35 | -0.37 | -0.41 | -1.95 | |
| Debt to equity | 0 | 0 | 0.15 | 0.29 | 0.76 | |
| Debt to assets | 0 | 0 | 0.11 | 0.19 | 0.34 | |
| Net debt to EBITDA | 1.55 | 40.64 | 0.62 | 1.41 | 0.37 | |
| Current ratio | 7.58 | 9.01 | 6.4 | 5.56 | 1.97 | |
| Interest coverage | 0 | 0 | 0 | -38.81 | -24.78 | |
| Income quality | 1.53 | 11.69 | 0.91 | 0.88 | 0.95 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.59 | 0.31 | 5.55 | 29.1 | 52.26 | |
| Research and developement to revenue | 1.33 | 0.8 | 14.59 | 88.8 | 152.35 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0.02 | 0.01 | 0.03 | 0.04 | 0.03 | |
| Capex to revenue | -0.03 | -0.01 | -0.49 | -3.72 | -6.2 | |
| Capex to depreciation | -0.68 | -0.24 | -0.9 | -1.27 | -1.33 | |
| Stock based compensation to revenue | 0.21 | 0.1 | 1.22 | 5.36 | 10.64 | |
| Graham number | 12.04 | 3.28 | 12.83 | 10.2 | 4.83 | |
| ROIC | -0.23 | -0.06 | -0.54 | -0.49 | -1.23 | |
| Return on tangible assets | -0.18 | -0.02 | -0.46 | -0.46 | -1.09 | |
| Graham Net | 4.73 | 3.77 | 2.42 | 2.01 | 0.2 | |
| Working capital | 94.73M | 74.93M | 70M | 89.99M | 24.35M | |
| Tangible asset value | 98.21M | 77.7M | 69.92M | 84.52M | 28.04M | |
| Net current asset value | 89.77M | 70.78M | 53.66M | 68.55M | 12.35M | |
| Invested capital | 0 | 0 | 0.15 | 0.29 | 0.76 | |
| Average receivables | 192K | 111.5K | 6.5K | 0 | 0 | |
| Average payables | 971.5K | 1.14M | 1.34M | 1.62M | 2.4M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 3.17 | 0.11 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 115.17 | 3.21K | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.21 | -0.03 | -0.65 | -0.67 | -2.42 | |
| Capex per share | -0.04 | -0.02 | -0.06 | -0.06 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q1
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0.01 | 0 | |
| Net income per share | -0.4 | -0.43 | -0.34 | -0.42 | 0.26 | |
| Operating cash flow per share | -0.37 | 0 | -0.32 | -0.41 | -0.27 | |
| Free cash flow per share | -0.39 | -0.02 | -0.33 | -0.42 | -0.27 | |
| Cash per share | 2.11 | 1.7 | 1.55 | 1.03 | 0.53 | |
| Book value per share | 1.62 | 1.2 | 1.08 | 0.65 | 0.27 | |
| Tangible book value per share | 1.59 | 1.17 | 1.05 | 0.62 | 0.25 | |
| Share holders equity per share | 1.62 | 1.2 | 1.08 | 0.65 | 0.27 | |
| Interest debt per share | 0.59 | 0.5 | 0.58 | 0.51 | 0.3 | |
| Market cap | 128.9M | 81.48M | 46.69M | 34.67M | 17.63M | |
| Enterprise value | 62.82M | 30.98M | 3.4M | 10.78M | 3.54M | |
| P/E ratio | -1.88 | -1.1 | -0.78 | -0.46 | 0.26 | |
| Price to sales ratio | 0 | 0 | 0 | 106.69 | 0 | |
| POCF ratio | -8.09 | 0 | -3.34 | -1.9 | -1.01 | |
| PFCF ratio | -7.79 | -99.25 | -3.29 | -1.81 | -1 | |
| P/B Ratio | 1.85 | 1.58 | 0.99 | 1.18 | 1 | |
| PTB ratio | 1.85 | 1.58 | 0.99 | 1.18 | 1 | |
| EV to sales | 0 | 0 | 0 | 33.17 | 0 | |
| Enterprise value over EBITDA | -3.91 | -1.62 | -0.26 | -0.62 | -0.2 | |
| EV to operating cash flow | -3.94 | 0 | -0.24 | -0.59 | -0.2 | |
| EV to free cash flow | -3.8 | -37.74 | -0.24 | -0.56 | -0.2 | |
| Earnings yield | -0.13 | -0.23 | -0.32 | -0.55 | 0.97 | |
| Free cash flow yield | -0.13 | -0.01 | -0.3 | -0.55 | -1 | |
| Debt to equity | 0.35 | 0.43 | 0.52 | 0.76 | 1.14 | |
| Debt to assets | 0.22 | 0.24 | 0.28 | 0.34 | 0.35 | |
| Net debt to EBITDA | 4.11 | 2.65 | 3.27 | 1.38 | 0.81 | |
| Current ratio | 4.3 | 3.13 | 2.73 | 1.97 | 1.4 | |
| Interest coverage | -24.55 | 29.36 | -20.43 | -26.73 | 0.71 | |
| Income quality | 0.93 | 0 | 0.98 | 0.99 | 0.94 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 13.77 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 41.77 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | |
| Capex to operating cash flow | 0.04 | 0 | 0.01 | 0.05 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | -2.65 | 0 | |
| Capex to depreciation | -1.69 | -1.09 | -0.53 | -2.25 | -0.49 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 2.56 | 0 | |
| Graham number | 3.82 | 3.41 | 2.88 | 2.49 | 1.27 | |
| ROIC | -0.17 | -0.24 | -0.19 | -0.33 | -1.02 | |
| Return on tangible assets | -0.16 | -0.2 | -0.17 | -0.29 | 0.31 | |
| Graham Net | 1.16 | 0.74 | 0.63 | 0.2 | -0.08 | |
| Working capital | 71.68M | 51.25M | 44.72M | 24.35M | 10.64M | |
| Tangible asset value | 68.22M | 50.15M | 45.65M | 28.04M | 16.11M | |
| Net current asset value | 52.5M | 34.49M | 30.36M | 12.35M | -2.45M | |
| Invested capital | 0.35 | 0.43 | 0.52 | 0.76 | 1.14 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.98M | 1.88M | 2.62M | 3.24M | 3.48M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.25 | -0.36 | -0.32 | -0.64 | 0.97 | |
| Capex per share | -0.01 | -0.02 | 0 | -0.02 | 0 |
AGTC Frequently Asked Questions
What is Applied Genetic Technologies Corporation stock symbol ?
Applied Genetic Technologies Corporation is a US stock , located in Alachua of Florida and trading under the symbol AGTC
What is Applied Genetic Technologies Corporation stock quote today ?
Applied Genetic Technologies Corporation stock price is $- today.
Is Applied Genetic Technologies Corporation stock public?
Yes, Applied Genetic Technologies Corporation is a publicly traded company.
Company Profile
- Volume Average 1.32M
- Employee 102
- CEO Ms. Susan Washer
- Headquarters Alachua,FLORIDA,US
- IPO Date 2014-03-27
-
Website
https://agtc.com 
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.
